Lilly-backed cell therapy biotech nabs new funds; Colorado biotech nets an acquisition

An Eli Lilly-backed cell therapy biotech has secured $50 million in Series A funds to bankroll CAR-NK therapies.

At the helm of the Shanghai-based Neukio Biotherapeutics is a leader with experience in the CAR-T cell therapy market, with Richard Liqun Wang having previously served as chief executive of the Fosun and Kite joint venture that landed the first CAR-T cell therapy approval in China last year. Kite and owner Gilead market the cell therapy product as Yescarta in the US.

Neukio raised the round with support from Lilly Asia Ventures, Sherpa Healthcare Partners and IDG Capital. The company previously snagged $40 million in what it characterized as an angel round in October 2021. The same investors took part in that financing.

The biotech, formed last year, is looking to make allogenic cell therapies “via the iPSC-CAR-NK axis,” according to its website. Neukio has 5,700 square meters of R&D and manufacturing…
Click here to view original post